U.S. flag An official website of the United States government
  1. Home
  2. News & Events
  3. Drug Master File (DMF) Workshop: GDUFA III Enhancements and Structured Data Submissions - 11/30/2022
  1. News & Events

Conference

Event Title
Drug Master File (DMF) Workshop: GDUFA III Enhancements and Structured Data Submissions
November 30, 2022


Date:
November 30, 2022
Time:
8:30 AM - 4:00 PM ET

 

Topics & Presentations

Speakers

Drug Master File (DMF) Workshop: GDUFA III Enhancements and Structured Data Submissions Keynote and Session 1

 

Keynote: Cloud-based Regulatory Submission and Assessment: ICH M4Q(R2) and FDA KASA Initiatives

Lawrence Yu
Director, Office of New Drug Products (ONDP)
Office of Pharmaceutical Quality (OPQ)
Center for Drug Evaluation and Research
(CDER) | US FDA
Rapporteur, ICH M4Q(R2) Expert Working Group

Closing out GDUFA II: Summary of DMF Performance

Benjamin Danso
Commander, United States Public Health Service
Regulatory Business Process Manager
Office of Program & Regulatory Operations (OPRO)
Office of Pharmaceutical Quality (OPQ)
Center for Drug Evaluation and Research (CDER) | US FDA

Introducing the DMF Enhancements in the GDUFA III Commitment Letter

Jayani Perera, PhD
Senior Chemist
Office of Pharmaceutical Quality (OPQ)
Center for Drug Evaluation and Research (CDER) | US FDA

GDUFA III Enhancements - Assessment of Solicited DMF Amendments

Jennifer Nguyen, PharmD
Senior Regulatory Business Process Manager
Office of Program and Regulatory Operations (OPRO)
Office of Pharmaceutical Quality (OPQ)
Center for Drug Evaluation and Research (CDER) | US FDA

Q&A Discussion Panel

Benjamin Danso, Jayani Perera, Jennifer Nguyen
and
David Skanchy
Commander, United States Public Health Service
Director
Division of Lifecycle API (DLAPI)
Office of New Drug Products (ONDP)
Office of Pharmaceutical Quality (OPQ)
Center for Drug Evaluation and Research (CDER) | US FDA

Drug Master File (DMF) Workshop: GDUFA III Enhancements and Structured Data Submissions Session 2

 

GDUFA III DMF Prior Assessments: Explanation and Overview

Erin Skoda, PhD
Branch Chief
Division of Lifecycle API
Office of New Drug Products (ONDP)
Center for Drug Evaluation and Research (CDER) | US FDA

GDUFA III Enhancements - DMF Prior Assessments

Jayani Perera, PhD
Senior Chemist
Office of Pharmaceutical Quality (OPQ)
Center for Drug Evaluation and Research (CDER) | US FDA

GDUFA III DMF Review Prior to ANDA Submission: Eligibility Criteria for the ANDA Submissions

Iain Margand, RPh
Commander, United States Public Health Service
Patent and Exclusivity Team, Division of Legal & Regulatory Support (DLRS)
Office of Generic Drug Policy (OGDP)
Office of Generic Drugs (OGD)
Center for Drug Evaluation and Research (CDER) | US FDA

GDUFA III Prior Assessment Process: Presumptive Q & A

Jayani Perera, PhD
Senior Chemist
Office of Pharmaceutical Quality (OPQ)
Center for Drug Evaluation and Research (CDER) | US FDA

Q&A Discussion Panel

Erin Skoda, Jayani Perera, Iain Margand, David Skanchy
and
Ziyang Su
Policy Lead
Division of Regulations, Guidance and Standards
Office of Policy for Pharmaceutical Quality (OPPQ)
Office of Pharmaceutical Quality (OPQ)
Center for Drug Evaluation and Research (CDER) | US FDA

Drug Master File (DMF) Workshop: GDUFA III Enhancements and Structured Data Submissions Session 3

 

The Future of FDA Quality Assessment Knowledge-Aided Assessment & Structured Application - KASA

Andre Raw, PhD
Associate Director for Science and Communication
Office of Lifecycle Drug Products (OLDP)
Office of Pharmaceutical Quality (OPQ)
Center for Drug Evaluation and Research (CDER) | US FDA

Modernization of Regulatory Submission

Larisa Wu, PhD
Associate Director for Science and Communication
Office of New Drug Products (ONDP)
Office of Pharmaceutical Quality (OPQ)
Center for Drug Evaluation and Research (CDER) | US FDA

Quick Guide to Creating a Structure-Data File (SD File) for Submissions

Marlene Kim
Chemist, Health Informatics Staff (HIS)
Office of Data, Analytics, & Research (ODAR)
Office of Digital Transformation (ODT)
Office of the Commissioner (OC)

Q&A Discussion Panel

Andre Raw, Larisa Wu, Marlene Kim, Erin Skoda
and
Barbara O. Scott
Review Chemist
Division of Lifecycle API
Office of New Drug Products (ONDP)
Office of Pharmaceutical Quality (OPQ)
Center for Drug Evaluation and Research (CDER) | US FDA

Drug Master File (DMF) Workshop: GDUFA III Enhancements and Structured Data Submissions Session 4 and Closing Remarks

 

Improving (Q)SAR Review with Structure-Data Files (SD Files)

Naomi L. Kruhlak, PhD
Scientific Lead
Computational Toxicology Consultation Service (CTCS)
Division of Applied Regulatory Science (DARS)
Office of Clinical Pharmacology (OCP)
Office of Translational Sciences (OTS) | CDER

What are UNIIs and How Do You Get Them?

Frank L. Switzer, PhD
Chemist
Health Informatics Staff
Office of Data, Analytics, And Research (ODAR)
Office of Digital Transformation (ODT)
Office of the Commissioner (OC) | US FDA

Machine Readable Synthetic Pathways in GSRS and KASA

Tyler Peryea
Health Informatics Staff
Office of Data, Analytics, And Research (ODAR)
Office of Digital Transformation (ODT)
Office of the Commissioner (OC) | US FDA

Q&A Discussion Panel

Naomi Kruhlak, Frank Switzer, Tyler Peryea and
David Green
Senior Pharmaceutical Quality Assessor
Division of Life Cycle API (DLAPI)
Office of New Drug Product (ONDP)
Office of Pharmaceutical Quality (OPQ)
Center for Drug Evaluation and Research (CDER) | US FDA

Closing Remarks

David Skanchy
Commander, United States Public Health Service
Director
Division of Lifecycle API (DLAPI)
Office of New Drug Products (ONDP)
Office of Pharmaceutical Quality (OPQ)
Center for Drug Evaluation and Research (CDER) | US FDA

 

Agenda

Visit CDER Small Business and Industry Assistance Page

ABOUT THIS EVENT

This conference is designed to cover two topics. First is to discuss the two Drug Master File (DMF) enhancements specified under the Generic Drug User Fee Amendments (GDUFA) III Commitment Letter which includes DMF review prior to ANDA submission and assessment of solicited DMF amendments outside of an application. This topic will help the industry better understand the changes in GDUFA III and its potential benefits. Second is an update on the future state of DMF submissions and assessments including discussion of Knowledge-Aided Assessment and Structured Application (KASA), Structure-Data (SD) files and Global Substance Registration Systems (GSRS) database. This topic will inform the industry of the agency’s modernization effort in Chemistry Manufacturing and Controls (CMC) submission to further streamline the assessment process and make the approval process more efficient.

INTENDED AUDIENCE

  • Regulatory affairs and manufacturing professionals with an interest in understanding new DMF aspects of GDUFA III
  • Manufacturers of active pharmaceutical ingredients (APIs) in support of an ANDA or NDA (AAM, APIC, PhRMA, EFPAI, JPMA, DIA)
  • DMF holders and ANDA applicants looking to gain knowledge about structured data and SD file submission to the agency
  • Regulatory Affairs Professionals or Agents
  • Foreign Regulatory Bodies
  • Compendia (USP, EP, JP)

TOPICS COVERED

  • New GDUFA III DMF enhancements and their potential benefits to industry and the GDUFA program
  • KASA and structured data submission overview
  • Structure-Data (SD) files overview: what they are, how to create them and how they are used to improve Quantitative Structure-Activity Relationships (Q)SAR review
  • What a Unique Ingredient Identifier (UNII) is and how to get one
  • Structured Synthetic Route data with GSRS and KASA
  • Future state of CMC submissions

FDA RESOURCES

KASA Resources

SD File Resources:

  • Questions on how to include the SD File in section S.3.2 of the eCTD: email [email protected]
  • Quick Guide to Creating a Structure-Data File (SD File) for DMF Submissions
  • Stop Re-drawing Chemicals! Implementation of
  • To obtain a UNII
Back to Top